Cleared Traditional

IMMUNO-PROD IND FLUORE TREPONE ANTIBODY ABSORPED (K853122) - FDA 510(k) Clearance

Class II Microbiology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K853122 · Immuno-Products Industries · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1985
Decision
56d
Days
Class 2
Risk

K853122 is an FDA 510(k) clearance for the IMMUNO-PROD IND FLUORE TREPONE ANTIBODY ABSORPED. Classified as Anti-human Globulin, Fta-abs Test (product code GMS), Class II - Special Controls.

Submitted by Immuno-Products Industries (So. Bound Brook, US). The FDA issued a Cleared decision on September 19, 1985 after a review of 56 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3830 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Immuno-Products Industries devices

Submission Details

510(k) Number K853122 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 25, 1985
Decision Date September 19, 1985
Days to Decision 56 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
46d faster than avg
Panel avg: 102d · This submission: 56d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GMS Anti-human Globulin, Fta-abs Test
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3830
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.